Drug Use-results Survey of TEPMETKO tablets 250 mg (METex14 skipping alterations, unresectable, advanced or recurrent non-small cell lung cancer)

Drug Use-results Survey of TEPMETKO tablets 250 mg (METex14 skipping alterations, unresectable, advanced or recurrent non-small cell lung cancer) - TEPMETKO 250 mg Investigation (Non-small cell lung cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046465

Enrollment

100

Registered

2021-12-24

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received at least 1 dose of this drug during the survey period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Investigate occurrence of interstitial lung disease, fluid retention, hepatic function disorder, renal impairment and QT interval prolongation	—

Countries

Japan

Contacts

Public ContactTatsuya Ogura

Merck Biopharma Co., Ltd. PMS Planning & Strategy

tatsuya.ogura@merckgroup.com03-6756-0791

Outcome results